Safety and tolerability of putaminal AADC gene therapy for Parkinson disease - Wikidata - wikimedia - TriplyDB

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

http://www.wikidata.org/entity/Q33731687

about

Gene therapy in Parkinson's disease: rationale and current status Oligonucleotide therapeutic approaches for Huntington disease An optogenetic toolbox designed for primates Theoretical Approaches to Lentiviral Mediated Neurotrophin Delivery in Potential Treatments of Parkinson's Disease Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives Lipopolyplex for Therapeutic Gene Delivery and Its Application for the Treatment of Parkinson's Disease Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease Parkinson's disease: gene therapies Parkinson's disease gene therapy: success by design meets failure by efficacy Glial-derived neurotrophic factor gene transfer for Parkinson's disease: anterograde distribution of AAV2 vectors in the primate brain Treating Parkinson's disease in the 21st century: can stem cell transplantation compete?Carbidopa-based modulation of the functional effect of the AAV2-hAADC gene therapy in 6-OHDA lesioned rats Noninvasive and targeted gene delivery into the brain using microbubble-facilitated focused ultrasound.Therapeutic potential of optogenetic neuromodulation Noninvasive, neuron-specific gene therapy can be facilitated by focused ultrasound and recombinant adeno-associated virus Enhancement of Blood-Brain Barrier Permeability and Delivery of Antisense Oligonucleotides or Plasmid DNA to the Brain by the Combination of Bubble Liposomes and High-Intensity Focused Ultrasound.Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy.A diagnostic approach for cerebral palsy in the genomic era.Systemic injection of AAV9-GDNF provides modest functional improvements in the SOD1G93A ALS rat but has adverse side effects.Current Experimental Studies of Gene Therapy in Parkinson's Disease Transduction of brain dopamine neurons by adenoviral vectors is modulated by CAR expression: rationale for tropism modified vectors in PD gene therapy Human/nonhuman primate AC-PC ratio--considerations for translational brain measurements Therapeutic efficacy of AAV8-mediated intrastriatal delivery of human cerebral dopamine neurotrophic factor in 6-OHDA-induced parkinsonian rat models with different disease progression.Subregional 6-[18F]fluoro-ʟ-m-tyrosine uptake in the striatum in Parkinson's disease.Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions.An optimized system for interventional magnetic resonance imaging-guided stereotactic surgery: preliminary evaluation of targeting accuracy.The current status of gene therapy for Parkinson's disease Regeneration of the MPTP-lesioned dopaminergic system after convection-enhanced delivery of AAV2-GDNF.Guided delivery of adeno-associated viral vectors into the primate brain A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease SAFETY AND TOLERABILITY OF MRI-GUIDED INFUSION OF AAV2-hAADC INTO THE MID-BRAIN OF NON-HUMAN PRIMATE.Capsid serotype and timing of injection determines AAV transduction in the neonatal mice brain.Novel platform for MRI-guided convection-enhanced delivery of therapeutics: preclinical validation in nonhuman primate brain.Effect of concentration on the accuracy of convective imaging distribution of a gadolinium-based surrogate tracer.Interventional MRI-guided putaminal delivery of AAV2-GDNF for a planned clinical trial in Parkinson's disease Gene therapy in mouse models of huntington disease.Gene therapy for the nervous system: challenges and new strategies.Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.

P2860

Q22241423-E2B77D06-A32D-42AD-BA48-25C5794EAA74 Q22306293-49D0EC95-BF59-4F3F-B942-24FC2CC90018 Q24623252-3C07CB34-7B9B-447A-BBDA-48F53EA55427 Q26746174-A6A717FB-2AE3-49EA-A2DC-C0B775EC29BE Q26747508-9347E622-F9E6-4C5A-AC10-177D189BF1DE Q26752578-0BBE8D78-4DDA-422A-B0D4-B746FDBE1133 Q26773485-D088E784-DE79-48CF-9DEF-96CE57228A20 Q26824184-6A8DA629-F673-4CBD-A49A-905F8CCF85E7 Q26851325-DDC6A109-2AAC-4A83-8A81-E3F5C401A348 Q27002651-4D62DF9D-1CEF-4A5C-8D6B-82265C10A2F0 Q27024152-A537C6E6-AC7B-4E7E-8F44-0E676DDECE06 Q27310170-E77B1CDA-B4D3-47FA-815B-A8E5BF7B11B2 Q27312535-81D67651-3368-4061-8438-65527E15F9EA Q28084334-05E3D73B-16B0-487B-A100-51569E67652A Q30394725-D6AA5D40-3771-4530-8F69-F9EEA7E7D831 Q30401360-FB31EA76-486C-4F37-ADEC-2E790BB974FB Q30531601-8BF40AF3-4591-46C8-B858-2B92FDE303E5 Q30605561-B0FDA102-C4F5-4486-8991-2A0A89EE38F3 Q30857266-C0CDE671-C128-4DE3-8CD5-70DED3DCBBEF Q33600773-8DC38F47-3692-48E8-B6F4-6B075F54F6B4 Q33627771-06724A9B-E3ED-418D-973F-6EFDC6C13326 Q33700352-B7BC82F1-2A61-4AB4-8CDF-88DB8D048A37 Q33780449-975A6BF7-485C-4867-9B9D-49D81BE6D842 Q33807060-6B22EA04-0086-455B-AC7F-1869700BBED3 Q33853332-BF16DC48-F478-4015-8240-ED27B3599328 Q33938435-4D8D6ECE-68D1-494C-B81C-F14B45C645C2 Q33973505-1DCEDB69-AF70-4692-B6EB-0DDC606BD0F0 Q33979379-E6F64D0E-ECAB-446B-A88D-FD799A6A460A Q34039452-4DAB21ED-FEFA-4F2F-B69C-7DB091A34820 Q34061373-E444B27F-3F77-4C1C-A706-3AE32B1877BF Q34209755-E30B4FFD-A8AF-4707-B48F-4BE1B7F1BEF8 Q34762396-F1CC120E-D077-4CF0-BF66-3D02AB5B60F2 Q34795088-7BCA6D59-A935-4FC8-AE60-A945F4DDCC50 Q34892014-3B23C118-AA30-4DA9-9CAD-97D86232D219 Q34954951-F594DFDC-0CCE-4F3F-92C6-82E05E009ADD Q35086686-2D1C0262-EBDC-4C60-B18B-7BE52F7C7402 Q35090208-E10C5742-3ADC-4E79-9C91-0048788B4969 Q35340196-3145BB53-082D-4877-B1F8-39CFCD17E92C Q35582092-B47CCB0A-829A-4E82-B92C-116FFD0D5F6B Q35614156-1874403C-FC0A-46C7-AA87-398F79101FF1

P2860

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

http://www.wikidata.org/entity/Q33731687

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

@ast

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

@en

type

label

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

@ast

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

@en

prefLabel

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

@ast

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

@en

P1433

Q33731687-07231114-DCBA-481E-A584-1FB46B95B88B

P1476

Q33731687-82513269-A3C1-4BC3-A5AA-9F2505BE99AE

P2093

Q33731687-0ED4DBC6-4948-4BD1-95D6-C1ACC4BDE3BA

Q33731687-17DF91A5-ECD3-4916-BF98-FA9F6AFC8B9C

Q33731687-26317A6A-1132-4892-A63E-AA5223068A53

Q33731687-4A562F02-527C-454B-B678-F45E2CA43CE3

Q33731687-72642E79-11B0-4194-86FB-F8126AA78022

Q33731687-80AFF0D3-639B-460E-8288-7A646E093349

Q33731687-932066AA-1E04-4964-9D5C-B5EC8D79A674

Q33731687-B0F567F8-078B-4D5E-B082-ED4C90485483

Q33731687-F4D41064-1262-44A0-968B-7069E9714A52

Q33731687-FCBFA295-D58B-4DD4-AB8A-16C5832CB074

P2860

Q33731687-0A7EB767-5222-4829-8E22-917201930F3B

Q33731687-0E81418C-87A1-4664-A737-F1341AFB6ECF

Q33731687-1AEF18F0-EA1E-4773-BDDF-98067DDC7BEF

Q33731687-2341CE57-7A13-495E-BE17-FA46B08FEEAE

Q33731687-26A0AAB4-CB1A-4334-8C40-13313BE43EEC

Q33731687-33DACC76-631A-40FF-BC48-AE0A558F93AD

Q33731687-3D4E05B6-2A11-4C23-8679-D541A1B3C3C8

Q33731687-421BC088-FB5F-4F2C-AB49-F4BB82496BCC

Q33731687-909E7F23-4D19-40B2-AD2D-5DB906E19E1F

Q33731687-A7225D80-BCF0-4ED4-BCF0-DAC6C4203814

P304

Q33731687-7979C546-5E3C-407D-891E-FD16EC707174

P31

Q33731687-05A3F596-73D8-4AA4-B101-757D1CEDE885

P356

Q33731687-B34C54DD-A9C8-460A-8EF9-496DB4900E29

P407

Q33731687-DB584596-FCAC-4450-BF64-39FB335911FE

P433

Q33731687-7492FA75-7223-48B0-A2E0-5D8AAACE5F44

P478

Q33731687-549B30B0-601D-4066-B43E-A9FF4398E2B1

P577

Q33731687-BE1C0C16-741F-40F3-95BF-2E7612CFFA89

P698

Q33731687-1EB855E6-B79E-4C0B-B31E-5DBF6205B9FC

P921

Q33731687-2D7CF4B5-783C-4925-B35A-35FBDC56D538

Q33731687-398ACEE2-7F9E-46AA-BD50-DA1A0C127178

P932

Q33731687-CE04B7A4-1120-4D81-887F-09AD362B819F

P356

WNL.0B013E3181C29356

P1433

P1476

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

@en

P2093

C W Christine

http://www.w3.org/2001/XMLSchema#string

H F VanBrocklin

http://www.w3.org/2001/XMLSchema#string

J F Wright

http://www.w3.org/2001/XMLSchema#string

J L Eberling

http://www.w3.org/2001/XMLSchema#string

K S Bankiewicz

http://www.w3.org/2001/XMLSchema#string

M J Aminoff

http://www.w3.org/2001/XMLSchema#string

P A Starr

http://www.w3.org/2001/XMLSchema#string

P S Larson

http://www.w3.org/2001/XMLSchema#string

R A Hawkins

http://www.w3.org/2001/XMLSchema#string

W J Jagust

http://www.w3.org/2001/XMLSchema#string

P2860

“Mini-mental state”

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

Development and validation of a geriatric depression screening scale: a preliminary report

Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects.

Adeno-associated virus vectors can be efficiently produced without helper virus.

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial.

Results from a phase I safety trial of hAADC gene therapy for Parkinson disease.

Recombinant adeno-associated virus: formulation challenges and strategies for a gene therapy vector.

AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters.

A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.

P304

1662-1669

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0B013E3181C29356

http://www.w3.org/2001/XMLSchema#string

P407

P433

20

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

2009-10-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19828868

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

2839805

http://www.w3.org/2001/XMLSchema#string